Den mulige relevans af behovet for > 45% reduktion af LDL- C og det forhold, at dette ville kunne tages i betragtning gennem individualiseret valg af startdosis, anerkendes i forvejen af CHMP for andre produkter af denne kategori.
The potential relevance of need of > 45% reduction of LDL-C, and that this could be taken into account in an individualised choice of start dose, has already been acknowledged by CHMP for other products of this class.